Genomenon Partners with Three Rare Disease Foundations to Advance Drug Development

The AI-driven geonomics company Genomenon said it entered into partnerships with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect to collaborate with them and their pharmaceutical industry partners to deliver genomic data with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.

Photo: Mike Klein, CEO of Genomenon

Genomenon delivers comprehensive genomic data for rare diseases that helps pharmaceutical companies identify the patients most likely to respond to clinical trials, provides evidence-based disease prevalence estimates for market assessment, and raises awareness of the diseases and any associated clinical trials and/or treatments to researchers and clinicians at the point of diagnosis.

Understanding rare diseases remains a significant challenge. A recent study revealed that traditional research sources are missing evidence for up to 70 percent of clinically encountered variants, information that is essential to developing treatments for genetic disorders. This lack of comprehensive data increases the risk of program failure in clinical trials.

“By putting critical information at the fingertips of researchers and clinicians seeking diagnoses for their patients, this new venture represents a shared mission to ensure that no patient goes undiagnosed or untreated,” said Mike Klein, CEO of Genomenon.

Author: Rare Daily Staff